Search Results - "Ornbjerg, L"

Validation and assessment of minimally clinically important difference of the unadjusted Health Assessment Questionnaire in a Danish cohort: uncovering ordinal bias by Ørnbjerg, LM, Christensen, KB, Tennant, A, Hetland, ML

“…Objectives: The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a widely used patient-reported outcome for functional disability in…”
Get full text

Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial by Raft, MB, Hetland, ML, Brahe, CH, Hørslev-Petersen, K, Midtbøll Ørnbjerg, L, Junker, P, Biln, N, Stengaard-Pedersen, K, Østergaard, M

“…14-3-3η is a proinflammatory mediator critical to joint destruction in rheumatoid arthritis (RA). We aimed to evaluate serum 14-3-3η for predicting disease…”
Get full text

Impact of patient-reported flares on radiographic progression and functional impairment in patients with rheumatoid arthritis: a cohort study based on the AMBRA trial by Kuettel, D, Primdahl, J, Christensen, R, Ørnbjerg, LM, Hørslev-Petersen, K

“…Objective: To investigate the impact of patient-reported flares on radiographic damage and disability in rheumatoid arthritis (RA). Method: Patients with…”
Get full text

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response by Mathew, A J, Lund, M L, Pedersen, M P, Rasmussen, S H, Glintborg, B, Loft, A G, Nissen, M J, Möller, B, Rodrigues, A M, Santos, F P, Rotar, Z, Tomšič, M, Relas, H, Peltomaa, R, Gudbjornsson, B, Löve, T J, Kocaer, S B, Koken Avsar, A, Midtbøll Ørnbjerg, L, Østergaard, M

“…To explore the registration of enthesitis among biologic-naïve patients with psoriatic arthritis (PsA) initiating tumour necrosis factor inhibitor (TNFi)…”
Get full text

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA) by Hørslev-Petersen, K, Hetland, M L, Ørnbjerg, L M, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Johansen, J S, Østergaard, M, Stengaard-Pedersen, K

“…To study clinical and radiographic outcomes after withdrawing 1 year's adalimumab induction therapy for early rheumatoid arthritis (eRA) added to a…”
Get more information

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial by Brahe, CH, Østergaard, M, Johansen, JS, Defranoux, N, Wang, X, Bolce, R, Sasso, EH, Ørnbjerg, LM, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Ammitzbøll, C, Jørgensen, A, Krintel, SB, Raun, J, Hetland, ML

“…Objectives: Measurement of serum biomarkers at disease onset may improve prediction of disease course in patients with early rheumatoid arthritis (RA). We…”
Get full text

Plasma haem oxygenase-1 may represent a first-in-class biomarker of oxidative stress in rheumatoid arthritis by Andersen, B B, Greisen, S, Stengaard-Pedersen, K, Junker, P, Hørslev-Petersen, K, Hetland, M Lund, Østergaard, M, Ørnbjerg, L Midtbøll, Hvid, M, Deleuran, B, Nielsen, M A

“…This study explores the early identification of rheumatoid arthritis (RA) patients at elevated risk of progression. Haem-oxygenase-1 (HO-1) is a marker of…”
Get full text

Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial by Møller-Bisgaard, S, Hørslev-Petersen, K, Ejbjerg, B, Hetland, ML, Christensen, R, Ørnbjerg, LM, Glinatsi, D, Møller, JM, Boesen, M, Stengaard-Pedersen, K, Madsen, OR, Jensen, B, Villadsen, JA, Hauge, EM, Bennett, P, Hendricks, O, Asmussen, K, Kowalski, M, Lindegaard, H, Bliddal, H, Krogh, NS, Ellingsen, T, Nielsen, AH, Larsen, L, Jurik, AG, Thomsen, HS, Østergaard, M

“…To compare the effect of treat-to-target-based escalations in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologics on clinical…”
Get full text

Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials by Brahe, CH, Dehlendorff, C, Østergaard, M, Johansen, JS, Ørnbjerg, LM, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Lindegaard, H, Hansen, I, Lottenburger, T, Jacobsen, S, Jurik, AG, Hetland, ML

“…Objective: To investigate serum interleukin-6 (IL-6), serum chitinase-3-like protein-1 (YKL-40), and plasma vascular endothelial growth factor (VEGF) as…”
Get full text

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors by Terslev, L, Ostergaard, Mikkel, Georgiadis, Stylianos, Brahe, Cecilie Heegaard, Ellegaard, Karen, Dohn, U M, Fana, Viktoria, Møller, Torsten, Juul, Lars, Huynh, Tuan Khai, Krabbe, Simon, Ornbjerg, L M, Glinatsi, Daniel, Røgind, Henrik, Hansen, Annette, Nørregaard, Jesper, Jacobsen, Søren, Jensen, Dorte V, Manilo, Natalia, Asmussen, Karsten, Boesen, Mikael, Rastiemadabadi, Zoreh, Morsel-Carlsen, Lone, Møller, Jakob Møllenbach, Krogh, Niels Steen, Hetland, Merete Lund

“…To identify predictors of flare in a 2-year follow-up study of patients with rheumatoid arthritis (RA) in sustained clinical remission tapering towards…”
Get full text

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial by Ørnbjerg, L. M., Østergaard, M., Jensen, T., Hørslev-Petersen, K., Stengaard-Pedersen, K., Junker, P., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Hetland, M. L., Slot, Ole, Nielsen, Lars Kjær, Skjødt, Henrik, Majgaard, Ole, Lorenzen, Tove, Horn, Hans Christian, Kowalski, Marcin, Johansen, Inger Lauge, Pedersen, Peter Mosborg, Manilo, Natalia, Bliddal, Henning

“…This study aims to investigate 1-year hand bone loss (HBL 1-year ) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and…”
Get full text

Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? - Results from the EuroSpA Collaboration by Georgiadis, S, Ornbjerg, L, Michelsen, B, Kvien, T, Di Giuseppe, D, Wallman, JK, Zavada, J, Provan, S, Rodrigues, AM, Santos, MJ, Rotar, Z, Nordstrom, D, Hokkanen, AM, Macfarlane, G, Jones, GT, van der Horst-Bruinsma, I, Hellamand, P, Ostergaard, M, Hetland, M

Get full text

BASDAI cut-offs for disease activity corresponding to ASDAS-ESR cut-offs in axial spondylarthritis - Results from the EuroSpA collaboration by Georgiadis, S, Ornbjerg, L, Michelsen, B, Kvien, T, Wallman, J, Di Giuseppe, D, Pavelka, K, Zavada, J, Provan, S, Santos, M, Rodrigues, A, Ciurea, A, Nissen, M, Codreanu, C, Mogosan, C, Rotar, Z, Tomsic, M, Macfarlane, G, Jones, G, Nordstrom, D, Hokkanen, A, van der Horst-Bruinsma, I, Hellamand, P, Ostergaard, M, Hetland, M

Get full text

Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice - Results from the EuroSpA Collaboration by Georgiadis, S, Linde, L, Ornbjerg, L, Rasmussen, SH, Askling, J, Michelsen, B, Di Giuseppe, D, Wallman, JK, Glintborg, B, Loft, AG, Bernardes, M, Matos, CO, Nordstrom, D, Kuusalo, L, Moeller, B, Nissen, M, Gudbjornsson, B, Love, T, Iannone, F, Kvien, T, Rotar, Z, Castrejon, I, Macfarlane, G, van de Sande, M, Hetland, M, Ostergaard, M

Get full text

The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration by Ahmadzay, ZF, Georgiadis, S, Pons, M, Hetland, M, Glintborg, B, Heberg, J, Christiansen, SN, Rasmussen, SH, Loft, AG, Castrejon, I, Otero-Valera, L, Zavada, J, Pavelka, K, Relas, H, Kuusalo, L, Moeller, B, Nissen, M, Rotar, Z, Pirkmajer, KP, Oliveira, DS, Cruz-Machado, AR, Michelsen, B, Kristianslund, E, Gudbjornsson, B, Grondal, GM, Laas, K, Hellamand, P, Sari, I, Di Giuseppe, D, Ostergaard, M, Ornbjerg, L

Get full text

Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching by Linde, Louise, Ørnbjerg, Lykke Midtbøll, Heegaard Brahe, Cecilie, Wallman, Johan Karlsson, Di Giuseppe, Daniela, Závada, Jakub, Castrejon, Isabel, Díaz-Gonzalez, Federico, Rotar, Ziga, Tomšič, Matija, Glintborg, Bente, Gudbjornsson, Bjorn, Geirsson, Arni Jon, Michelsen, Brigitte, Kristianslund, Eirik Klami, Santos, Maria José, Barcelos, Anabela, Nordström, Dan, Eklund, Kari K, Ciurea, Adrian, Nissen, Michael, Akar, Servet, Hejl Hyldstrup, Lise, Krogh, Niels Steen, Hetland, Merete Lund, Østergaard, Mikkel

“…Abstract Objective To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the…”
Get full text

Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe by Michelsen, B, Ostergaard, M, Nissen, M, Ciurea, A, Moeller, B, Ornbjerg, L, Zavada, J, Glintborg, B, MacDonald, A, Laas, K, Nordstrom, D, Gudbjornsson, B, Iannone, F, Hellamand, P, Kvien, T, Rodrigues, AM, Codreanu, C, Rotar, Z, Castrejon, I, Wallman, JK, Vencovsky, J, Loft, AG, Heddle, M, Vorobjov, S, Hokkanen, AM, Grondal, GM, Sebastiani, M, van de Sande, M, Kristianslund, E, Santos, MJ, Mogosan, C, Tomsic, M, Diaz-Gonzalez, JF, Di Giuseppe, D, Hetland, M

Get full text

Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration by Pons, M, Rasmussen, SH, Christiansen, SN, Michelsen, B, Glintborg, B, Gudbjornsson, B, Grondal, GM, Vencovsky, J, Loft, AG, Rotar, Z, Pirkmajer, KP, Nissen, M, Moeller, B, Macfarlane, G, Jones, GT, Iannone, F, Caporali, RF, Laas, K, Vorobjov, S, Di Giuseppe, D, Coskun, BN, Yagiz, B, Provan, S, Fagerli, K, Castrejon, I, Otero-Valera, L, van de Sande, M, Van der Horst-Bruinsma, I, Nordstrom, D, Kuusalo, L, Vieira-Sousa, E, Bernardes, M, Olofsson, T, Baranov, J, Hetland, M, Ostergaard, M, Ornbjerg, L

Get full text

One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment by Ørnbjerg, Lykke Midtbøll, Rugbjerg, Kathrine, Georgiadis, Stylianos, Rasmussen, Simon Horskjær, Lindström, Ulf, Pavelka, Karel, Yilmaz, Neslihan, Favalli, Ennio Giulio, Nissen, Michael J, Michelsen, Brigitte, Vieira-Sousa, Elsa, Jones, Gareth T, Ionescu, Ruxandra, Relas, Heikki, Sanchez-Piedra, Carlos, Tomšič, Matija, Geirsson, Arni Jon, van der Horst-Bruinsma, Irene, Askling, Johan, Loft, Anne Gitte, Nekvindova, Lucie, Direskeneli, Haner, Iannone, Florenzo, Ciurea, Adrian, Fagerli, Karen Minde, Santos, Maria José, Macfarlane, Gary J, Codreanu, Catalin, Eklund, Kari, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, Rusman, Tamara, Østergaard, Mikkel, Hetland, Merete Lund

“…To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor…”
Get full text

Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable? by Georgiadis, Stylianos, Ørnbjerg, Lykke Midtbøll, Michelsen, Brigitte, Kvien, Tore K, Di Giuseppe, Daniela, Wallman, Johan K, Závada, Jakub, Provan, Sella A, Kristianslund, Eirik Klami, Rodrigues, Ana Maria, Santos, Maria José, Rotar, Žiga, Perdan Pirkmajer, Katja, Nordström, Dan, Macfarlane, Gary J, Jones, Gareth T, van der Horst-Bruinsma, Irene, Hellamand, Pasoon, Østergaard, Mikkel, Hetland, Merete Lund

“…Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate…”
Get full text